Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating glaucoma

Abstract

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating glaucoma. The traditional Chinese medicine composition is prepared from the following raw materials: rhizoma acori graminei, semen cassiae, herba cistanche, radix puerariae, semen celosiae, radix codonopsis, fructus viticis, fructus lycii, semen plantaginis, radix paeoniae alba, fructus corni, liquorice root, semen cuscutae, rhizoma cimicifugae, nux prinsepiae, flos chrysanthemi, flos buddlejae, rhizoma chuanxiong, wine-processed rhizoma polygonati, radix rehmanniae praeparata, cortex phellodendri chinensis and radix astragali seu hedysari. Through reasonable compatibility of the components, the traditional Chinese medicine composition has the advantages of obvious effect and good safety when being used for preventing and treating glaucoma, especially acute glaucoma, and the traditional Chinese medicine composition including the Xiaoyingming tablet can obviously improve the retina histomorphology, increase the thickness of a reticular layer in the retina and relieve retina injury after being used for treating a model mouse; the survival rate of the retinal ganglion cells is improved. The result further shows that the traditional Chinese medicine composition including the Xiaoming tablets has great potential in the aspect of preventing and treating glaucoma.

Description

Technical Field

[0001] The present application relates to the field of medical technology, and in particular to the use of a traditional Chinese medicine composition in the preparation of a medicine for preventing and treating glaucoma. Background Art

[0002] Glaucoma is a blinding ophthalmic disease, mainly due to damage to the optic nerve caused by increased intraocular pressure. It is the second largest cause of blindness in the world, second only to cataracts, and the first irreversible blinding disease. Glaucoma is characterized by progressive loss of retinal ganglion cells (RGC) and visual field defects. RGC damage under the participation of multiple mechanisms is the cause of irreversible loss of visual function in glaucoma patients. The specific role of traditional medicine in RGC apoptosis and acute / chronic glaucoma is still unclear. At present, the main methods for treating glaucoma include drug therapy, laser therapy and surgical treatment. Laser therapy and surgical treatment are not universal due to certain risks, high technical difficulty, high expected treatment costs, and great differences in efficacy among different patients. Therefore, there is an urgent need for a drug that can be used to significantly improve glaucoma in the clinic.

[0003] Zhanyanming Tablets are included in the 2020 edition of the Chinese Pharmacopoeia. The prescription is derived from the traditional prescriptions Zhujing Pills in Taiping Huimin Hejijufang and Yiqi Congming Decoction in Dongyuan Shixiaofang. It is composed of 22 kinds of Chinese medicines, including Acorus calamus, Cassia seed, Cistanche deserticola, Pueraria root, Amaranthus amaranthus, Codonopsis pilosula, Vitex rotundifolia, Lycium barbarum, Plantago seed, White peony root, Cornus officinalis, Licorice, Cuscuta seed, Cimicifuga heracleifolia, Rhizoma rutaecarpa, Chrysanthemum, Buddismia odorata, Ligusticum chuanxiong, Polygonatum odoratum, Rehmannia root, Phellodendron chinense, and Astragalus. It has the functions of nourishing the liver and kidney, removing cataracts and improving eyesight. It is used for dryness and discomfort caused by liver and kidney deficiency, monocular diplopia, soreness of waist and knees, or mild vision loss. At present, there are no reports that Zhanyanming Tablets have the effect of preventing and treating glaucoma. Summary of the invention

[0004] Based on this, the purpose of this application includes providing the use of a Chinese medicine composition in the preparation of a drug for preventing and treating glaucoma.

[0005] The technical solution of this application is as follows:

[0006] The invention provides an application of a traditional Chinese medicine composition in preparing a medicine for preventing and treating glaucoma. The traditional Chinese medicine composition comprises the following raw materials: calamus, cassia seed, cistanche deserticola, kudzu root, amaranth fruit, codonopsis pilosula, vitex rotundifolia, wolfberry fruit, plantain seed, white peony root, cornus officinalis, liquorice, dodder seed, cimicifuga heracleifolia, rutina seed, chrysanthemum, buddlejac, ligusticum chuanxiong, polygonatum sibiricum, rehmannia root, phellodendron chinense and astragalus.

[0007] In one embodiment, the Chinese medicine composition includes the following raw materials, measured by mass: 20-30 parts of Acorus calamus, 30-40 parts of Cassia seed, 30-40 parts of Cistanche deserticola, 30-40 parts of Pueraria root, 30-40 parts of Amaranthus aquatica, 40-50 parts of Codonopsis pilosula, 30-40 parts of Vitex rotundifolia, 40-50 parts of Lycium barbarum, 30-40 parts of Plantago seed, 40-50 parts of White Peony Root, 20-30 parts of Cornus officinalis, 20-30 parts of Licorice, 60-70 parts of Cuscuta seed, 1-10 parts of Cimicifuga heracleifolia, 30-40 parts of Rhizoma Cynomorii, 30-40 parts of Chrysanthemum, 30-40 parts of Buddleja buddleja, 30-40 parts of Ligusticum chuanxiong, 30-40 parts of Polygonatum odoratum, 60-70 parts of Rehmannia root, 30-40 parts of Phellodendron chinense and 40-50 parts of Astragalus.

[0008] In one embodiment, the Chinese medicine composition includes the following raw materials, measured by mass: 21-23 parts of Acorus calamus, 29-31 parts of Cassia seed, 36-38 parts of Cistanche deserticola, 36-38 parts of Pueraria root, 29-31 parts of Amaranthus aquatica, 47-49 parts of Codonopsis pilosula, 29-31 parts of Vitex rotundifolia, 47-49 parts of Lycium barbarum, 36-38 parts of Plantago seed, 44-46 parts of White Peony Root, 23-25 ​​parts of Cornus officinalis, 21-23 parts of Licorice, 60-62 parts of Cuscuta seed, 6-8 parts of Cimicifuga heracleifolia, 36-38 parts of Rhizoma Cynomorii, 36-38 parts of Chrysanthemum, 36-38 parts of Buddleja buddleja, 29-31 parts of Ligusticum chuanxiong, 36-38 parts of Polygonatum sibiricum, 60-62 parts of Rehmannia root, 29-31 parts of Phellodendron chinense and 47-49 parts of Astragalus.

[0009] In one embodiment, the Chinese medicine composition includes the following raw materials, measured by mass: 22 parts of Acorus calamus, 30 parts of Cassia seed, 37 parts of Cistanche deserticola, 37 parts of Pueraria root, 30 parts of Amaranthus aquatica, 48 parts of Codonopsis pilosula, 30 parts of Vitex rotundifolia, 48 parts of Lycium barbarum, 37 parts of Plantago seed, 45 parts of White Peony Root, 24 parts of Cornus officinalis, 22 parts of Licorice, 61 parts of Cuscuta seed, 7 parts of Cimicifuga heracleifolia, 37 parts of Semen Polygoni Multiflori, 37 parts of Chrysanthemum, 37 parts of Buddleja buddleja, 30 parts of Ligusticum chuanxiong, 37 parts of Polygonatum odoratum, 61 parts of Rehmannia root, 30 parts of Phellodendron chinense and 48 parts of Astragalus.

[0010] In one embodiment, the Chinese medicine composition is a Zhanyanming preparation.

[0011] In one embodiment, the dosage form of the anti-blind preparation includes pills, powders, ointments, tablets, granules, lozenges, capsules, aqueous solutions or tinctures.

[0012] In one embodiment, the glaucoma is acute glaucoma.

[0013] In one embodiment, the drug further comprises a pharmaceutically acceptable excipient.

[0014] In one embodiment, the drug is a blinding pill.

[0015] In one embodiment, the drug is administered by intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

[0016] Compared with the prior art, this application has the following beneficial effects:

[0017] This application provides a use of a Chinese medicine composition in the preparation of a drug for preventing and treating glaucoma. After the various components in the Chinese medicine composition are reasonably matched, they have the advantages of obvious effect and good safety when used to prevent and treat glaucoma, especially acute glaucoma. Specifically, the Chinese medicine composition including the Zhanyanming tablet can significantly improve the retinal tissue morphology, increase the thickness of the retinal inner reticular layer, reduce retinal damage, and improve the survival rate of retinal ganglion cells after treating model mice. This result further shows that the Chinese medicine composition including the Zhanyanming tablet has great potential in preventing and treating glaucoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0019] Figure 1 : This is the HE staining result in Example 1, wherein Blank refers to the normal control group, I / R refers to the disease model group, ZYM refers to the drug treatment group, GCL refers to the ganglion cell layer cells, IPL refers to the inner plexiform layer of the retina, INL refers to the inner nuclear layer of the retina, and ONL refers to the outer nuclear layer of the retina.

[0020] Figure 2 This is a graph showing the results of reducing retinal damage by oral administration of Zanyanming in Example 1, wherein the ordinate refers to the thickness of the inner retinal plexiform layer, the abscissa Blank refers to the normal control group, I / R refers to the disease model group, and ZYM refers to the drug treatment group.

[0021] Figure 3 This is a graph showing the results of reducing the loss of RGC cells by oral gavage in Example 1, wherein Blank refers to the normal control group, I / R refers to the disease model group, and ZYM refers to the drug treatment group. DETAILED DESCRIPTION

[0022] In order to make the above-mentioned purpose, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below. In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present invention, so the present invention is not limited by the specific embodiments disclosed below.

[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0024] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0025] As used herein, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0026] Herein, "pharmaceutically acceptable salt" refers to a salt suitable for use as a drug formed by any compound in the structure shown and an acid or base. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one type of salt is a salt formed by the compound of the present application and an acid. Acids suitable for forming salts include but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid. Another type of salt is a salt formed by the compound of the present application and a base. Suitable bases for forming salts include but are not limited to alkali metal salts (such as sodium salts or potassium salts), alkaline earth metal salts (such as magnesium salts or calcium salts), ammonium salts (such as lower alkanolammonium salts and other pharmaceutically acceptable amine salts), such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0027] As used herein, "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, etc. Rice oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffered saline; (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0028] In the present invention, the "composition" may be a combination of a plurality of substances, and further, may be used in combination or may be a mixture of the combination.

[0029] As used herein, "drug" includes any agent, compound, composition or mixture that provides physiological and / or pharmacological effects in vivo or in vitro, and often provides beneficial effects. The scope of the physiological and / or pharmacological effects of the "drug" in vivo is not particularly limited, and may be systemic effects or may only produce effects locally. The activity of the "drug" is not particularly limited, and may be an active substance that can interact with other substances, or may be an inert substance that does not interact.

[0030] Herein, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0031] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values ​​of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0032] Only some numerical ranges are specifically disclosed herein. However, any lower limit can be combined with any upper limit to form an unclearly recorded range; and any lower limit can be combined with other lower limits to form an unclearly recorded range, and any upper limit can be combined with any other upper limit to form an unclearly recorded range. In addition, each individually disclosed point or single value itself can be combined with any other point or single value as a lower limit or upper limit or with other lower limits or upper limits to form an unclearly recorded range. The use of numerical ranges represented by endpoints includes all numbers within the range and any range within the range, for example, 1 to 5 includes 1, 1.1, 1.3, 1.5, 1.7, 1.9, 2, 2.2, 2.5, 2.7, 2.75, 2.8, 3, 3.2, 3.4, 3.6, 3.80, 4, 4.2, 4.4, 4.6, 4.8 and 5, etc.

[0033] The percentage contents involved in this application, unless otherwise specified, refer to mass percentage for solid-liquid mixing and solid-solid mixing, and refer to volume percentage for liquid-liquid mixing.

[0034] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0035] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0036] The invention provides an application of a traditional Chinese medicine composition in preparing a medicine for preventing and treating glaucoma. The traditional Chinese medicine composition comprises the following raw materials: calamus, cassia seed, cistanche deserticola, kudzu root, amaranth fruit, codonopsis pilosula, vitex rotundifolia, wolfberry fruit, plantain seed, white peony root, cornus officinalis, liquorice, dodder seed, cimicifuga heracleifolia, rutina seed, chrysanthemum, buddlejac, ligusticum chuanxiong, polygonatum sibiricum, rehmannia root, phellodendron chinense and astragalus.

[0037] In some of the examples, the Chinese medicine composition includes the following raw materials, measured by mass: 20-30 parts of Acorus calamus, 30-40 parts of Cassia seed, 30-40 parts of Cistanche deserticola, 30-40 parts of Pueraria root, 30-40 parts of Amaranthus amarantifolia, 40-50 parts of Codonopsis pilosula, 30-40 parts of Vitex rotundifolia, 40-50 parts of Lycium barbarum, 30-40 parts of Plantago seed, 40-50 parts of White Peony Root, 20-30 parts of Cornus officinalis, 20-30 parts of Licorice, 60-70 parts of Cuscuta seed, 1-10 parts of Cimicifuga heracleifolia, 30-40 parts of Rhizoma Cynomorii, 30-40 parts of Chrysanthemum, 30-40 parts of Buddlejac, 30-40 parts of Ligusticum chuanxiong, 30-40 parts of Polygonatum odoratum, 60-70 parts of Rehmannia root, 30-40 parts of Phellodendron chinense and 40-50 parts of Astragalus.

[0038] In some of the examples, the Chinese medicine composition includes the following raw materials, measured by mass: 21-23 parts of Acorus calamus, 29-31 parts of Cassia seed, 36-38 parts of Cistanche deserticola, 36-38 parts of Pueraria root, 29-31 parts of Amaranthus aquatica, 47-49 parts of Codonopsis pilosula, 29-31 parts of Vitex rotundifolia, 47-49 parts of Lycium barbarum, 36-38 parts of Plantago seed, 44-46 parts of White Peony Root, 23-25 ​​parts of Cornus officinalis, 21-23 parts of Licorice, 60-62 parts of Cuscuta seed, 6-8 parts of Cimicifuga heracleifolia, 36-38 parts of Rhizoma Cynomorii, 36-38 parts of Chrysanthemum, 36-38 parts of Buddleja buddleja, 29-31 parts of Ligusticum chuanxiong, 36-38 parts of Polygonatum sibiricum, 60-62 parts of Rehmannia root, 29-31 parts of Phellodendron chinense and 47-49 parts of Astragalus.

[0039] In some of the examples, the Chinese medicine composition includes the following raw materials, measured by mass: 22 parts of Acorus calamus, 30 parts of Cassia seed, 37 parts of Cistanche deserticola, 37 parts of Pueraria root, 30 parts of Amaranthus aquatica, 48 parts of Codonopsis pilosula, 30 parts of Vitex rotundus, 48 ​​parts of Lycium barbarum, 37 parts of Plantago seed, 45 parts of White Peony Root, 24 parts of Cornus officinalis, 22 parts of Licorice, 61 parts of Cuscuta seed, 7 parts of Cimicifuga heracleifolia, 37 parts of Semen Polygoni Multiflori, 37 parts of Chrysanthemum, 37 parts of Buddleja buddleja, 30 parts of Ligusticum chuanxiong, 37 parts of Polygonatum odoratum, 61 parts of Rehmannia root, 30 parts of Phellodendron chinense and 48 parts of Astragalus.

[0040] In some of these examples, the Chinese medicine composition is a Zhanyanming preparation.

[0041] In some examples, the dosage form of the anti-cancer preparation includes pills, powders, ointments, tablets, granules, lozenges, capsules, liquids or tinctures. It is understandable that the Chinese medicine composition of the present application can be added with different pharmaceutically acceptable excipients to prepare suitable clinical dosage forms, which include but are not limited to the dosage forms described herein.

[0042] In some of these examples, the glaucoma is acute glaucoma. Specifically, the technicians of the present application unexpectedly discovered through research that oral administration of the Zhanyanming tablet can effectively protect the progressive damage of retinal ganglion cells (RGCs) in an acute high intraocular pressure model and promote their survival.

[0043] In some examples, the drug also includes pharmaceutically acceptable excipients. These pharmaceutically acceptable excipients include, but are not limited to, diluents, wetting agents, adhesives, disintegrants, lubricants, color and flavor regulators, solvents, solubilizers, cosolvents, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, local analgesics, pH regulators, isotonic or isotonic regulators, etc.

[0044] In some of the examples, the drug is Zhanyanming Tablets. Zhanyanming Tablets are a product produced by Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. It is a tablet composed of 22 Chinese medicinal herbs including Acorus calamus, Cassia seed, Cistanche deserticola, Pueraria root, Amaranthus australis, Codonopsis pilosula, Vitex rotundifolia, Lycium barbarum, Plantago seed, White peony root, Cornus officinalis, Licorice root, Cuscuta seed, Cimicifuga heracleifolia, Semen rutaecarpa, Chrysanthemum, Buddismia odorata, Ligusticum chuanxiong, Polygonatum sibiricum, Rehmannia root, Phellodendron chinense and Astragalus membranaceus, which has the effects of nourishing the liver and kidney, removing cataracts and improving eyesight. The main herbs in the prescription are Rehmannia root and Cuscuta seed, which nourish the kidney and improve the essence, nourish the liver and improve eyesight; the auxiliary herbs are Lycium barbarum, Codonopsis pilosula and Astragalus membranaceus, which nourish the liver and kidney and replenish the middle qi; the adjuvant Ligusticum chuanxiong promotes blood circulation. According to the principle of "treating different diseases with the same method" in traditional Chinese medicine, Zhanyanming Tablets have certain advantages in the treatment of inflammatory diseases such as glaucoma and optic neuritis. There is no report on the use of Zhanyanming tablets in the prevention and treatment of glaucoma. Specifically, the technicians of this application explored the effects of Zhanyanming in reducing retinal damage and inhibiting apoptosis of retinal ganglion cells. These results provide new insights into the pathogenesis of glaucoma and potential therapeutic targets.

[0045] In some of these examples, the drug may be administered using a suitable route of administration based on clinical needs. It is understandable that the route of administration of the drug includes but is not limited to: intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

[0046] In summary, the technical personnel of the present application unexpectedly discovered through research that the Chinese medicine composition including Zhanyanming tablets can significantly improve the retinal tissue morphology, increase the thickness of the retinal inner retinal layer, reduce retinal damage, and improve the survival rate of retinal ganglion cells after treating model mice. This result further shows that the Chinese medicine composition including Zhanyanming tablets has great potential in preventing and treating glaucoma.

[0047] The following is further described in conjunction with specific embodiments. The raw materials involved in the following specific embodiments, unless otherwise specified, can all be commercially available; the instruments used, unless otherwise specified, can all be commercially available; the processes involved, unless otherwise specified, are all routinely selected by those skilled in the art.

[0048] The following are specific embodiments.

[0049] Example 1

[0050] 1. Experimental Grouping

[0051] This experiment selected 6-8 week old male C57BL / 6J mice, and the right eyes of the animals were used for the experiment, and the left eyes were used as parallel controls. The animals were adapted for 7 days after purchase and then the experiment began. The operation was gentle to minimize pain.

[0052] The experiment includes:

[0053] The acute intraocular hypertension model was divided into the following three groups: normal control group (Blank), model group (I / R), and ZYM treatment group (ZYM).

[0054] 2. Experimental Intervention

[0055] (1) Animal models

[0056] Acute high intraocular pressure I / R model: After anesthesia of C57BL / 6 mice, the infusion tube was connected to a 30G needle for anterior chamber puncture, and the infusion bottle was maintained at 150cm. The continuous perfusion time was 1h. The intraocular pressure was about 110mmHg (1mmHg=0.133 kPa) during the operation, which was qualified. The control group of mice was a sham operation group. After the operation, tobramycin eye ointment was applied to prevent infection, and the mice were placed back at room temperature and kept warm. The whole operation process should be gentle to minimize the pain.

[0057] The normal control group underwent sham operation and had no increased intraocular pressure.

[0058] (2) Drug intervention:

[0059] Treatment group: 7 days before modeling, the mice were gavaged with the drug solution of Zhanyanming once a day (dose: 600 mg / kg), the model was established on the 8th day, and the mice were killed for detection on the 7th day after modeling. The concentration of the drug solution of Zhanyanming was 24 mg / mL, and the dosage of the drug solution was 0.25 mL per 10 g of mouse body weight to meet the requirement of a drug concentration of 600 mg / kg. The preparation method is to take an appropriate amount of the powder of the Zhanyanming tablets without the film, suspend it in physiological saline, and shake it well before gavage.

[0060] Modeling group: The mice were gavaged with normal saline every day for 7 days before modeling, and the modeling was performed on the 8th day. The mice were killed and tested on the 7th day after modeling.

[0061] 3. After the mice were killed, the retinal tissue was removed from the eyeball and stained with HE and RBPMS suspension immunofluorescence staining respectively; the retinal tissue was transferred to a glass slide under a microscope, and the tissue was radially spread with a wet brush, with the ganglion cell layer facing up; the slide was sealed with anti-fluorescence quenching sealing agent. Images of retinal ganglion cells were collected under a fluorescence microscope (objective magnification 20×); after collecting the images, the number of RGCs in each image was manually counted using the ImageJ software (NIH, US) Cell Counter program.

[0062] 3. Experimental Results

[0063] 1. Retinal histomorphology

[0064] The mouse eyeballs were paraffin-embedded and sectioned, and retinal damage was directly observed by HE staining. Figure 1 , Figure 2 As shown in the figure, HE results showed that retinal damage after modeling mainly occurred in the inner retina, with visible cell edema, vacuolation, nuclear condensation, and enhanced staining. In the I / R modeling group, the retinal inner plexiform layer (IPL) was significantly thinned, the number of cells in the retinal ganglion cell layer (GCL) was reduced, and vacuolar changes were obvious. Intragastric administration of the Zhanyanming tablet can alleviate retinal damage, and the thickness of the IPL was significantly thickened compared with the I / R group (42.09±1.12μm vs 24.86±0.69μm, p<0.005), and the difference was statistically significant.

[0065] 2. Retinal ganglion cell survival

[0066] The mouse retina was taken for flat-mounting and RBPMS suspension immunofluorescence staining was performed to observe the changes in the number of RGC cells. The survival rate was expressed as the percentage ratio of the RGCs cell count of the experimental eye to the control eye. Figure 3 As shown in the figure, the results showed that 7 days after modeling, the number of RGC cells in the retina of the I / R group decreased by about 50%, and only 57.95±1.35% of RGCs survived. However, oral administration of the eye-catching tablets could reduce the loss of RGC cells, and the survival rate of RGC cells increased to 66.97±1.80%, with statistically significant differences between the groups.

[0067] The above results indicate that oral administration of Zhanyanming tablets can effectively protect RGCs from damage and promote their survival in the acute ocular hypertension model.

[0068] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0069] The above-described embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be construed as limiting the scope of the patent application. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent application shall be subject to the attached claims, and the description may be used to interpret the content of the claims.

Claims

1. Use of a Chinese medicine composition in the preparation of a drug for preventing and treating glaucoma, the Chinese medicine composition comprising the following raw materials: Acorus calamus, Cassia seed, Cistanche deserticola, Pueraria root, Amaranthus australis, Codonopsis pilosula, Vitex rotundifolia, Lycium barbarum, Plantago seed, White peony root, Cornus officinalis, Licorice, Cuscuta seed, Cimicifuga heracleifolia, Semen rutaecarpa, Chrysanthemum, Buddleja buddleja, Ligusticum chuanxiong, Polygonatum sibiricum, Rehmannia root, Phellodendron chinense and Astragalus.

2. The use according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by mass: 20-30 parts of Acorus calamus, 30-40 parts of Cassia seed, 30-40 parts of Cistanche deserticola, 30-40 parts of Pueraria root, 30-40 parts of Amaranthus aquatica, 40-50 parts of Codonopsis pilosula, 30-40 parts of Vitex rotundifolia, 40-50 parts of Lycium barbarum, 30-40 parts of Plantago seed, 40-50 parts of White Peony Root, 20-30 parts of Cornus officinalis, 20-30 parts of Licorice, 60-70 parts of Cuscuta seed, 1-10 parts of Cimicifuga heracleifolia, 30-40 parts of Rhizoma Cynomorii, 30-40 parts of Chrysanthemum, 30-40 parts of Buddlejac, 30-40 parts of Ligusticum chuanxiong, 30-40 parts of Polygonatum odoratum, 60-70 parts of Rehmannia root, 30-40 parts of Phellodendron chinense and 40-50 parts of Astragalus.

3. The use according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by mass: 21-23 parts of Acorus calamus, 29-31 parts of Cassia seed, 36-38 parts of Cistanche deserticola, 36-38 parts of Pueraria root, 29-31 parts of Amaranthus aquatica, 47-49 parts of Codonopsis pilosula, 29-31 parts of Vitex rotundifolia, 47-49 parts of Lycium barbarum, 36-38 parts of Plantago seed, 44-46 parts of White Peony Root, 23-25 ​​parts of Cornus officinalis, 21-23 parts of Licorice, 60-62 parts of Cuscuta seed, 6-8 parts of Cimicifuga heracleifolia, 36-38 parts of Rhizoma Cynomorii, 36-38 parts of Chrysanthemum, 36-38 parts of Buddlejac, 29-31 parts of Ligusticum chuanxiong, 36-38 parts of Polygonatum sibiricum, 60-62 parts of Rehmannia root, 29-31 parts of Phellodendron chinense and 47-49 parts of Astragalus.

4. The use according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by mass: 22 parts of Acorus calamus, 30 parts of Cassia seed, 37 parts of Cistanche deserticola, 37 parts of Pueraria root, 30 parts of Amaranthus aquatica, 48 parts of Codonopsis pilosula, 30 parts of Vitex rotundifolia, 48 parts of Lycium barbarum, 37 parts of Plantago seed, 45 parts of White Peony Root, 24 parts of Cornus officinalis, 22 parts of Licorice, 61 parts of Cuscuta seed, 7 parts of Cimicifuga heracleifolia, 37 parts of Semen Polygoni Multiflori, 37 parts of Chrysanthemum, 37 parts of Buddleja buddleja, 30 parts of Ligusticum chuanxiong, 37 parts of Polygonatum odoratum, 61 parts of Rehmannia root, 30 parts of Phellodendron chinense and 48 parts of Astragalus.

5. The use according to claim 1, characterized in that: The Chinese medicine composition is a Zhanyanming preparation.

6. The use according to claim 5, characterized in that: The dosage form of the anti-eye-moving preparation includes pills, powders, ointments, tablets, granules, lozenges, capsules, aqueous solutions or tinctures.

7. The use according to any one of claims 1 to 6, characterized in that: The glaucoma is acute glaucoma.

8. The use according to any one of claims 1 to 6, characterized in that: The drug also includes pharmaceutically acceptable excipients.

9. The use according to any one of claims 1 to 6, characterized in that: The medicine is a pill for blinding the eyes.

10. The use according to any one of claims 1 to 6, characterized in that: The administration route of the drug is intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

Images